Take Control of Patient Safety and Quality Control with InsightRX
Just last week, ConsortiEX proudly announced our new InsightRX Passive Audit Monitoring module.
Be Compliant with Confidence, DSCSA Compliance as a Service
Understanding the rules and regulations behind DSCSA Compliance can be a daunting task. As deadlines pass, the FDA regularly updates what it means to be compliant. ConsortiEX is proud to offer DSCSA Compliance as a Service (CaaS). Our CaaS module removes the burden of being compliant from the dispenser community with[...]
Address Quality Control, Re-insourcing CSP Production with a Central Fill Model
Today, cost and quality issues surrounding compounded sterile preparations (CSP’s) have nearly every major health system investigating what it takes to re-insource production. Most are looking at a hub and spoke approach, where their central-fill Batch Compounding can support the CSP production needs of all the[...]
Come see what You've been Missing, ConsortiEX is Attending ASHP Midyear
ConsortiEX is proudly attending ASHP Midyear. Stop by Booth 900 to see how our intuitive Pharmacy-Focused ERP solutions can enhance your patient safety, ensure quality control, and simplify compliance, first-hand and in-person. Our new InsightRX Passive Audit Monitoring hood will be on display.
InsightRX Passive Audit Monitoring: See What Others Miss
Introducing InsightRX Passive Audit Monitoring: See what others miss.
Recent FDA Guidance Sparks Concerns from Industry Leaders
Several key industry players have issued responses to the FDA in regard to the recent draft guidance on the use of Product Identifiers, and the policy on grandfathered product, in compliance with the Drug Supply Chain Security Act (DSCSA).
FDA Releases Final Guidance on Upcoming Product Identifier Requirements
On Sep. 9, 2018, the FDA released a Final Guidance regarding the use of product identifiers on packages and homogenous cases of product as mentioned in the Drug Supply Chain Security Act (DSCSA).
FDA Commissioner Details Steps to Ensure the Quality of and Preserve Access to Compounded Drugs
The practice of compounding medicines can provide important public health opportunities. The FDA’s compounding program – including implementation of the compounding provisions of the law – is a priority for the agency. We recognize that in delivering on implementation commitments, we must balance the need to preserve[...]